RNA Stock Analysis
RN
Uncovered
Avidity Biosciences Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
4.89
Dividend yield
—
Shares outstanding
70.808 B
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). The company is headquartered in San Diego, California and currently employs 186 full-time employees. The company went IPO on 2020-06-12. The firm utilizes its AOC platform to design, engineer and develop therapeutics, which combine specificity of monoclonal antibodies (mAbs), with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with such therapeutics. Its lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1 (DM1) a rare monogenic muscle disease. The Company’s advancing and expanding pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy (DMD), and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy (FSHD). AOC 1020 consists of its mAb, which is designed to bind to TfR1 conjugated with a siRNA targeted to DUX4 mRNA to be administered as an intravenous infusion.